{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:35:38Z","timestamp":1777347338640,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.breast.2024.103742","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:41:09Z","timestamp":1715827269000},"page":"103742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["\u201cPositioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper\u201d"],"prefix":"10.1016","volume":"76","author":[{"given":"Pierfranco","family":"Conte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Llombart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mart\u00ecn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-2827","authenticated-orcid":false,"given":"Francesca","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2024.103742_bib1","unstructured":"https:\/\/ecis.jrc.ec.europa.eu\/pdf\/Breast_cancer_2022-Oct_2023.pdf [n.d]."},{"key":"10.1016\/j.breast.2024.103742_bib2","article-title":"How we treat patients with metastatic HER2-positive breast cancer","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2024.103742_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.breast.2024.103742_bib4","article-title":"Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: data from the GIM14\/BIOMETA study","volume":"72","author":"Di Maio","year":"2023","journal-title":"Breast. Edinb. Scotl."},{"key":"10.1016\/j.breast.2024.103742_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2024.103742_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102527","article-title":"Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review","volume":"115","author":"M\u00fcller","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103742_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211066677","article-title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","volume":"14","author":"Simmons","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.breast.2024.103742_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2024.103742_bib11","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2\u2013positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102618","article-title":"Tucatinib's journey from clinical development to clinical practice: new horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread","volume":"120","author":"Criscitiello","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103742_bib14","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with her2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103742_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2024.103742_bib16","first-page":"65","article-title":"Using Delphi technique to build consensus in practice","volume":"9","author":"Giannarou","year":"2014","journal-title":"International Journal of Business Science & Applied Management (IJBSAM), ISSN 1753-0296, International Journal of Business Science & Applied Management, s.l."},{"key":"10.1016\/j.breast.2024.103742_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.12968\/bjtr.1996.3.12.14731","article-title":"The Delphi method: a useful tool for the allied health researcher","volume":"3","author":"Walker","year":"1996","journal-title":"Br. J. Ther. Rehabil."},{"key":"10.1016\/j.breast.2024.103742_bib18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2023.41.16_suppl.1014","article-title":"Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: a French multicentre retrospective study","volume":"41","author":"Frenel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2023.41.16_suppl.1051","article-title":"Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer","volume":"41","author":"Anders","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100501","article-title":"Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2024.103742_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-Positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2024.103742_bib22","series-title":"HER2CLIMB-02: primary analysis of a randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Abstract presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9","author":"Hurvitz","year":"2023"},{"key":"10.1016\/j.breast.2024.103742_bib23","doi-asserted-by":"crossref","first-page":"P4","DOI":"10.1158\/1538-7445.SABCS22-P4-01-10","article-title":"Abstract P4-01-10: evaluating the safety of tucatinib in combination with trastuzumab and capecitabine for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer in a real-world setting","volume":"83","author":"Moore","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2024.103742_bib24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1200\/JCO.2020.38.15_suppl.1043","article-title":"Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)","volume":"38","author":"Okines","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T21:09:43Z","timestamp":1758834583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"alternative-id":["S0960977624000730"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103742","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cPositioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper\u201d","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103742"}}